The purpose of the study is to assess how safe the medicine is and whether it shows early signs that it can shrink tumors when used alone or with the hormone blocker. Participants start with low doses that are gradually increased while doctors watch for side effects, known as dose‑limiting toxicities, and determine the highest dose that can be given safely, called the maximum tolerated dose. After the safe dose is found, more patients receive that dose for several treatment cycles, with regular clinic visits, blood tests, and imaging scans to see if the tumors are responding. The study follows a phase 1/2 trial design, beginning with a safety‑focused part and then moving to a larger group to look at tumor response and how long the benefit lasts.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

The purpose of the study is to find out whether the medication can slow the narrowing of the valve and improve the ability to exercise. Participants are randomly assigned to receive either the study drug or the placebo for about a year, with regular clinic visits. During the study, doctors will use an echocardiogram (an ultrasound picture of the heart) to see how big the valve opening is, and a peak VO2 test, measured during a CPET (a breathing and heart test done while exercising), to check how well the body uses oxygen. A CT scan (a detailed X‑ray picture) will also be performed to look at calcium buildup in the valve. If the valve becomes too narrow, doctors may discuss procedures such as TAVR (a catheter‑based valve replacement) or SAVR (surgical valve replacement).

Throughout the trial, participants will be monitored for any side effects, and safety checks will be done at each visit. The study team will collect information about health changes and any additional treatments needed, while keeping participants’ personal information confidential.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

After the first treatment with apalutamide and hormone therapy, the study compares continued treatment with apalutamide plus docetaxel and hormone therapy. Treatment is given over time, with regular study visits and follow-up checks. During the study, doctors watch for changes in the cancer, possible side effects, and how long the treatment continues to work. The study is Phase III, which means it is a late-stage trial designed to better understand how well this treatment approach works and how safe it is.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

The purpose of the study is to confirm whether MV140 is safe and helpful in reducing repeated urinary tract infections. The trial lasts about 15 months after treatment begins. Over this time, participants are followed for new infection episodes, and study visits are used to check symptoms and general health. The study also looks at side effects and how the treatment affects daily life.

The vaccine used in the study contains inactive forms of common bacteria that can cause urinary tract infections: Klebsiella pneumoniae, Escherichia coli, Enterococcus faecalis, and Proteus vulgaris. These bacteria are not alive in the vaccine. The treatment is given as a small spray under the tongue.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The purpose of the study is to find out whether adding ianalumab to the usual treatment leads to a better disease response than placebo, using the SRI-4 score at week 60 as the main measure. Participants are randomly assigned to receive either the drug or placebo for about a year, with regular clinic visits for safety checks and disease assessments while they continue their regular medicines; the dose of steroids may be lowered if the disease improves.

Researchers will record how many participants show improvement in disease activity, avoid serious flare‑ups, and are able to reduce steroid use to 5 mg per day or less. They will also monitor for side effects and collect blood samples to check drug levels and any immune reaction against the drug. The study ends after the 60‑week treatment period, followed by a short follow‑up phase.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

During the study, some participants will receive the active medicine, while others will receive a placebo. The research involves monitoring how the medicine affects the body over a period of time to see if it can change the way the disease progresses. The course of the study includes regular check-ups to observe any changes in health or how the lungs are functioning.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

The research involves two different approaches to treatment. In the first approach, ziftomenib is used alongside a nonintensive therapy consisting of venetoclax and azacitidine. In the second approach, ziftomenib is combined with an intensive therapy known as 7+3, which includes cytarabine and daunorubicin hydrochloride. Some participants may receive a placebo instead of ziftomenib to allow for a comparison between the different treatment methods.

During the study, participants will receive their assigned medications through different methods, such as oral pills or intravenous administration, which is the delivery of medicine directly into a vein. The study will monitor how long patients live and the time until the disease begins to grow again. This process helps determine if adding the new drug to standard treatments improves the long-term outcomes for people with these specific genetic forms of leukemia.

Participants in the study will be randomly assigned to receive either the active medication or a placebo. The study is double-blind, meaning that neither the participants nor the researchers will know which specific treatment is being administered during the course of the trial. The process involves monitoring changes in Forced Vital Capacity, which is a measurement of the total amount of air a person can exhale from their lungs after taking a deep breath. The study will track these changes and other health factors over a period of time to see how the medication affects the progression of the disease.

During the study, the way the body absorbs, distributes, and removes the medication will be examined. This process is known as pharmacokinetics. Researchers will look at how much of the drug remains in the blood and how much is removed through urine or during the blood cleaning process. The study will also monitor safety by observing vital signs and conducting various clinical tests.

The main goal of the study is to see how well each medicine cleans the bowel by measuring the cleanliness using a scoring system called the Boston Bowel Preparation Scale. The study will also look at how well children can follow the instructions for taking the medicine, how easy it is to drink, how it tastes, and whether children experience any unwanted effects from the medicine. Participants will be randomly assigned to receive either PLENVU or sodium picosulfate, meaning it will be decided by chance which medicine they get, similar to flipping a coin. The doctor performing the colonoscopy will not know which medicine the child received, which helps make the comparison fair.

During the study, children will take the bowel cleansing medicine at home before coming to the hospital or clinic for their colonoscopy. They or their parents will keep track of how much of the medicine they were able to drink and answer questions about how they felt while taking it. The colonoscopy will be performed as planned, and the doctor will score how clean the bowel is. After the colonoscopy, there will be a follow-up period to check on the child’s safety and well-being. The study is expected to start enrolling participants in early 2026 and finish in early 2027.

Participants in this study will already be taking other medications for their condition but will continue on stable doses of these medicines throughout the study. The study medication or placebo will be taken daily for 12 weeks. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving placebo during the treatment period. The maximum daily amount of BP1.4979 that can be given is 40 milligrams.

During the study, participants will have several visits where doctors will assess how severe their obsessive compulsive symptoms are using questionnaires and rating scales. These assessments will measure things like the frequency and intensity of unwanted thoughts and repetitive behaviors, overall functioning, and mood. The doctors will also monitor for any side effects or problems that might occur during treatment. The study will help determine whether this new medication could be a useful option for treating people with moderate to severe obsessive compulsive disorder who have not responded well enough to existing treatments.

The trial has two parts. The first part is a safety run-in phase where a small group of patients will receive BNT113 combined with pembrolizumab to check if the combination is safe and well-tolerated. The second part is a randomized phase where patients will be assigned by chance to receive either the combination of BNT113 and pembrolizumab or pembrolizumab alone. During the trial, doctors will monitor how the cancer responds to treatment and will check for any side effects. Patients will need to have regular visits, blood tests, and scans to see how well the treatment is working.

The trial will measure several outcomes including how long patients live, how long it takes before the cancer grows or spreads, and whether the cancer shrinks or disappears. Doctors will also carefully track any side effects that occur during treatment. The trial will use imaging scans to measure changes in tumor size and will follow patients for up to several years to gather information about the long-term effects of these treatments.

Participants in this study will have been diagnosed with Parkinson’s Disease and will already be taking medication for their condition for at least three months. The study will look at whether prasinezumab can delay the time it takes for movement problems to get worse. Prasinezumab will be given through an intravenous infusion, which means it will be delivered directly into a vein. The study will measure various aspects of how participants move and function, including detailed assessments of motor function, which refers to how well a person can control their body movements.

During the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. This includes checking for infusion-related reactions, which are responses that can happen when medication is given through a vein. Regular health checks will be performed, including measurements of vital signs such as blood pressure and heart rate, blood tests, and assessments of overall wellbeing. The study will also track changes in the amount of Parkinson’s Disease medication that participants need to take over time, as well as how participants feel about changes in their condition.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

The purpose of the study is to find out if BHV-8000 can slow down the worsening of symptoms in people with early Parkinson’s Disease. The study will measure this by looking at how long it takes for symptoms to get worse based on a rating scale that asks about daily activities. The study will also use a special type of brain scan called DaT-SPECT, which uses a substance called ioflupane that is injected into a vein. This scan helps doctors see the activity of certain brain cells that produce a chemical called dopamine, which is important for movement. When these cells are not working properly, it suggests the disease is progressing.

People in the study will take the study medication or placebo for up to 48 weeks. During this time, doctors will regularly check how the disease is affecting movement and daily activities using different rating scales. They will also monitor safety by checking for any unwanted effects and doing laboratory tests. The study will compare two different doses of BHV-8000 to placebo to see which dose works better and is safe for people with early Parkinson’s Disease.

During the study, people will receive different doses of RO7268489 or placebo in addition to their regular ocrelizumab treatment. The study will look at how well the medication works by checking if disability gets worse over time. This will be measured by looking at walking ability, hand function, and thinking skills. The study will also check how safe the medication is by watching for any unwanted effects and by doing regular health checks including blood tests and heart monitoring.

People taking part will need to wear a device that measures how they walk. The study will also measure the levels of certain substances in the blood to understand how the medication works in the body. The study will last for several years and will compare the results between people taking RO7268489 and those taking placebo to determine if the medication is helpful in slowing down the progression of multiple sclerosis.

The study is divided into different parts for adults and adolescents. For adults, there is an induction phase and a maintenance phase. During the induction phase, the study will look at whether icotrokinra can help bring the disease under control compared to placebo. This part lasts 12 weeks. If participants respond well to the treatment during induction, they may continue into the maintenance phase, which lasts 40 weeks. During this time, the study will check if icotrokinra can keep the disease under control. For adolescents aged 12 to 17 years, the study focuses on the maintenance phase to see if icotrokinra can keep their condition under control after they have responded to the treatment.

Participants in this study will need to have been diagnosed with Ulcerative Colitis at least 12 weeks before joining. The study will involve regular assessments to measure how active the disease is and how well the treatment is working. The medication is given as a film-coated tablet taken by mouth. The study is expected to run for several years to gather information about the long-term effects of this treatment.

The study is divided into different phases to test how well the medication works. In the first phase, called the induction phase, the goal is to see if icotrokinra can help reduce symptoms and improve the condition of the intestines after about 12 weeks of treatment. The study will look at whether participants have fewer symptoms and whether the inflammation in their intestines has improved. In the second phase, called the maintenance phase, participants who responded well to the treatment will continue to receive either icotrokinra or placebo for a longer period, up to about 40 weeks. This phase will check if the medication can help keep the disease under control over time and prevent symptoms from coming back.

Participants in this study must be adults who have been diagnosed with Crohn’s Disease for at least 12 weeks before joining the study. They need to have active disease with symptoms such as frequent loose stools or abdominal pain, and this must be confirmed by an examination of the intestines that shows inflammation and ulcers. Participants should have previously tried other treatments for Crohn’s Disease, such as steroids or other medications including biologics, but these treatments either did not work well enough, stopped working over time, or caused problems that made them difficult to tolerate. The study will last several years and will involve regular visits to monitor how well the treatment is working and to check for any side effects.

The purpose of this study is to see how well these treatment combinations work against the lung cancer in patients who have the specific EGFR mutations. The study will look at whether the treatments can slow down or stop the cancer from growing or spreading. Patients in the study will receive their assigned treatment combination and will be monitored regularly by the doctors to check how the cancer is responding and to watch for any side effects. The study is designed as an open-label trial, which means that both the patients and the doctors will know which treatment is being given.

During the study, patients will have regular visits where doctors will perform tests and examinations to measure the size of the cancer and see if it is getting smaller, staying the same, or growing. The study will follow patients for several years to gather information about how long the treatment keeps the cancer under control and how patients feel while taking the medications. This information will help doctors understand whether these treatment combinations could be useful options for patients with this type of lung cancer in the future.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study will involve people with mild to moderate Alzheimer’s Disease, who will receive either the study medications or placebo for 24 weeks. The medications are being tested to see if they can help improve cognitive function (thinking abilities) and daily functioning in people with Alzheimer’s Disease.

During the study, participants will take the medication daily and attend regular check-ups where their mental abilities and overall condition will be assessed. The study will track any changes in participants’ ability to think, perform daily activities, and their overall health status. Healthcare providers will monitor participants’ safety throughout the study period.

The purpose of this research is to evaluate how safe and well-tolerated TP-122 is when given through a nebulizer (a device that turns medicine into a fine mist for breathing) every 8 hours for 7 days. The treatment will be given alongside standard medical care to adults who are on breathing machines in intensive care units.

During the study, participants will receive either the new treatment plus standard care or standard care alone. The research team will monitor patients’ health through various medical tests, including blood work, vital signs, and heart measurements. They will also track how well patients recover from their infection and how long they need to stay in intensive care.